SELECTED ABSTRACTS FOR POSTER PRESENTATIONS
IN ALPHABETIC ORDER ACCORDING TO THE NAME OF THE FIRST AUTHOR
TRIALS IN PROGRESS
Poster 38: A TWO-PART PHASE 2 STUDY OF ITACITINIB IMMEDIATE RELEASE IN PATIENTS
WITH PRIMARY OR SECONDARY MYELOFIBROSIS WHO HAVE RECEIVED PRIOR
RUXOLITINIB AND/OR FEDRATINIB MONOTHERAPY
Andrew Kuykendall, Lea Burke, Mani Lakshminarayanan, Philomena Colucci
Poster 39: A PHASE 1/2 STUDY OF INCB000928 AS MONOTHERAPY OR IN COMBINATION
WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS
(INCB 00928-104)
Stephen T. Oh, Jean-Jacques Kiladjian, Francesca Palandri, Jason Gotlib, Sanjay Mohan,
Haris Ali, Ekatherine Asatiani, Francis Seguy, Feng Zhou, Srdan Verstovsek
Poster 40: ADORE: A RANDOMIZED, OPEN-LABEL, PHASE 1/2, OPEN-PLATFORM STUDY
EVALUATING SAFETY AND EFFICACY OF NOVEL RUXOLITINIB COMBINATIONS
IN PATIENTS WITH MYELOFIBROSIS
Andrew Perkins, Kate Burbury, Thomas Lehmann, David Ross, Andreas Reiter, Vikas
Gupta, Claire Harrison, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Marielle
Wondergem, Robert Pack, Monika Wroclawska, Celine Wilke, Angela Zhang, Florian
Heidel
Poster 41: A PHASE 1 STUDY OF INCB057643 MONOTHERAPY IN PATIENTS WITH
RELAPSED OR REFRACTORY MYELOFIBROSIS (INCB 57643-103)
Pankit Vachhani, Christine Lihou, Gongfu Zhou, Fred Zheng
Poster 42: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF
RUXOLITINIB PLUS PARSACLISIB IN PATIENTS WITH JAK- AND PI3K-INHIBITOR
TREATMENT–NAÏVE MYELOFIBROSIS
Abdulraheem Yacoub, Sue Erickson-Viitanen, Feng Zhou, Albert Assad
Poster 43: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF
PARSACLISIB PLUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS WHO
HAVE SUBOPTIMAL RESPONSE TO RUXOLITINIB
Abdulraheem Yacoub, Michael Stouffs, Feng Zhou, Albert Assad
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES